José Manuel Afonso Moreira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7154421/publications.pdf

Version: 2024-02-01

70 papers 2,739 citations

31 h-index

147566

51 g-index

71 all docs

71 docs citations

71 times ranked

6043 citing authors

#	Article	IF	CITATIONS
1	Proteomic Characterization of the Interstitial Fluid Perfusing the Breast Tumor Microenvironment. Molecular and Cellular Proteomics, 2004, 3, 327-344.	2.5	278
2	Identification of Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstitial Fluid in High Risk Breast Cancer Patients. Molecular and Cellular Proteomics, 2005, 4, 492-522.	2. 5	200
3	The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer, 2003, 3, 30.	1.1	128
4	ErbB2-Driven Breast Cancer Cell Invasion Depends on a Complex Signaling Network Activating Myeloid Zinc Finger-1-Dependent Cathepsin B Expression. Molecular Cell, 2012, 45, 764-776.	4.5	112
5	Contribution of Na ⁺ ,HCO ₃ ^{â°'} â€cotransport to cellular pH control in human breast cancer: A role for the breast cancer susceptibility locus NBCn1 (SLC4A7). International Journal of Cancer, 2013, 132, 1288-1299.	2.3	104
6	Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment. Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130098.	1.8	91
7	Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. Molecular Oncology, 2015, 9, 1169-1185.	2.1	91
8	Upâ€regulated Proteins in the Fluid Bathing the Tumour Cell Microenvironment as Potential Serological Markers for Early Detection of Cancer of the Breast. Molecular Oncology, 2010, 4, 65-89.	2.1	88
9	Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts. BMC Cancer, 2010, 10, 444.	1.1	77
10	Nucleosome structure of the yeast CHA1 promoter: analysis of activation-dependent chromatin remodeling of an RNA-polymerase-II-transcribed gene in TBP and RNA pol II mutants defective invivo in response to acidic activators. EMBO Journal, 1998, 17, 6028-6038.	3 . 5	71
11	Expression of the Tumor Suppressor Protein 14-3-3 $\ddot{l}f$ Is Down-regulated in Invasive Transitional Cell Carcinomas of the Urinary Bladder Undergoing Epithelial-to-Mesenchymal Transition. Molecular and Cellular Proteomics, 2004, 3, 410-419.	2.5	70
12	Down-regulation of the Tumor Suppressor Protein 14-3-3 $\ddot{l}f$ Is a Sporadic Event in Cancer of the Breast. Molecular and Cellular Proteomics, 2005, 4, 555-569.	2. 5	66
13	Loss of Expression of the Adipocyte-type Fatty Acid-binding Protein (A-FABP) Is Associated with Progression of Human Urothelial Carcinomas. Molecular and Cellular Proteomics, 2005, 4, 570-581.	2.5	64
14	Tumor interstitial fluid â€" A treasure trove of cancer biomarkers. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2259-2270.	1.1	64
15	CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. Journal of Cell Biology, 2014, 204, 713-727.	2.3	64
16	The net acid extruders NHE1, NBCn1 and MCT4 promote mammary tumor growth through distinct but overlapping mechanisms. International Journal of Cancer, 2018, 142, 2529-2542.	2.3	63
17	Chromatin-mediated transcriptional regulation by the yeast architectural factors NHP6A and NHP6B. EMBO Journal, 2000, 19, 6804-6813.	3.5	60
18	Proteomic Profiling of Mammary Carcinomas Identifies C7orf24, a î³-Glutamyl Cyclotransferase, as a Potential Cancer Biomarker. Journal of Proteome Research, 2010, 9, 3941-3953.	1.8	55

#	Article	IF	Citations
19	Molecular pathology of breast apocrine carcinomas: A protein expression signature specific for benign apocrine metaplasia. FEBS Letters, 2006, 580, 2935-2944.	1.3	48
20	Towards discovery-driven translational research in breast cancer. FEBS Journal, 2004, 272, 2-15.	2.2	45
21	Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer. Molecular and Cellular Proteomics, 2010, 9, 161-177.	2.5	45
22	Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research. Molecular and Cellular Proteomics, 2003, 2, 369-377.	2.5	44
23	Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a wellâ€defined cohort. Molecular Oncology, 2009, 3, 220-237.	2.1	43
24	Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development. Frontiers in Oncology, 2013, 3, 313.	1.3	42
25	Proteomic Profiling of Triple-negative Breast Carcinomas in Combination With a Three-tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor Negative Breast Cancer. Molecular and Cellular Proteomics, 2013, 12, 381-394.	2.5	40
26	Impact of proteomics on bladder cancer research. Pharmacogenomics, 2004, 5, 381-394.	0.6	37
27	TIMP-1 Increases Expression and Phosphorylation of Proteins Associated with Drug Resistance in Breast Cancer Cells. Journal of Proteome Research, 2013, 12, 4136-4151.	1.8	36
28	Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. Tumor Biology, 2015, 36, 4327-4338.	0.8	36
29	Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. BMC Cancer, 2016, 16, 34.	1.1	35
30	High level PHGDH expression in breast is predominantly associated with keratin 5â€positive cell lineage independently of malignancy. Molecular Oncology, 2015, 9, 1636-1654.	2.1	34
31	Apocrine Cysts of the Breast. Molecular and Cellular Proteomics, 2006, 5, 462-483.	2.5	33
32	Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Molecular Oncology, 2007, 1 , 97-119.	2.1	32
33	A single lysis solution for the analysis of tissue samples by different proteomic technologies. Molecular Oncology, 2008, 2, 368-379.	2.1	31
34	15-Prostaglandin Dehydrogenase Expression Alone or in Combination with ACSM1 Defines a Subgroup of the Apocrine Molecular Subtype of Breast Carcinoma. Molecular and Cellular Proteomics, 2008, 7, 1795-1809.	2.5	31
35	The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. BMC Genomics, 2016, 17, 442.	1.2	25
36	Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: Relationship between CK15+ progenitor/amplified cells and preâ€malignant lesions and invasive disease. Molecular Oncology, 2007, 1, 321-349.	2.1	24

#	Article	IF	CITATIONS
37	Tissue proteomics of the human mammary gland: Towards an abridged definition of the molecular phenotypes underlying epithelial normalcy. Molecular Oncology, 2010, 4, 539-561.	2.1	24
38	A Combined Proteome and Ultrastructural Localization Analysis of 14-3-3 Proteins in Transformed Human Amnion (AMA) Cells. Molecular and Cellular Proteomics, 2008, 7, 1225-1240.	2.5	23
39	FABP7 and HMGCS2 Are Novel Protein Markers for Apocrine Differentiation Categorizing Apocrine Carcinoma of the Breast. PLoS ONE, 2014, 9, e112024.	1.1	23
40	Let-7 microRNA controls invasion-promoting lysosomal changes via the oncogenic transcription factor myeloid zinc finger-1. Oncogenesis, 2018, 7, 14.	2.1	20
41	Allosteric regulation of AMP-activated protein kinase by adenylate nucleotides and small-molecule drugs. Biochemical Society Transactions, 2019, 47, 733-741.	1.6	19
42	Release of transcriptional repression via ErbB2-induced, SUMO-directed phosphorylation of myeloid zinc finger-1 serine 27 activates lysosome redistribution and invasion. Oncogene, 2019, 38, 3170-3184.	2.6	17
43	Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance. Cancers, 2021, 13, 1290.	1.7	17
44	Topoisomeraseâ€1 gene copy aberrations are frequent in patients with breast cancer. International Journal of Cancer, 2015, 137, 2000-2006.	2.3	14
45	Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening. Stem Cells, 2017, 35, 1898-1912.	1.4	13
46	Datin, a yeast poly(dA:dT)-binding protein, behaves as an activator of the wild-type ILV1 promoter and interacts synergistically with Reb1p. Molecular Genetics and Genomics, 1998, 258, 95-103.	2.4	12
47	Neither Reb1p nor Poly(dA·dT) Elements Are Responsible for the Highly Specific Chromatin Organization at the ILV1Promoter. Journal of Biological Chemistry, 2002, 277, 3202-3209.	1.6	12
48	Proteomic analysis of tissue samples in translational breast cancer research. Expert Review of Proteomics, 2014, 11, 285-302.	1.3	12
49	Predictive value of combined analysis of proâ€ <scp>NPY</scp> and <scp>ERG</scp> in localized prostate cancer. Apmis, 2018, 126, 804-813.	0.9	12
50	Proteomic strategies in bladder cancer: From tissue to fluid and back. Proteomics - Clinical Applications, 2008, 2, 974-988.	0.8	11
51	Metallopeptidase inhibitor 1 (TIMPâ€1) promotes receptor tyrosine kinase câ€Kit signaling in colorectal cancer. Molecular Oncology, 2019, 13, 2646-2662.	2.1	11
52	Functional Proteomic Profiling of Triple-Negative Breast Cancer. Cells, 2021, 10, 2768.	1.8	10
53	Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer. PLoS ONE, 2017, 12, e0188827.	1.1	9
54	Purification and characterization of bioactive his6-tagged recombinant human tissue inhibitor of metalloproteinases-1 (TIMP-1) protein expressed at high yields in mammalian cells. Protein Expression and Purification, 2014, 101, 157-164.	0.6	8

#	Article	IF	CITATIONS
55	Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. International Journal of Cancer, 2015, 137, 2470-2477.	2.3	8
56	Immunoexpression Analysis and Prognostic Value of BLCAP in Breast Cancer. PLoS ONE, 2012, 7, e45967.	1.1	8
57	Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 6082.	1.8	7
58	TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in <i>KRAS</i> mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. Oncotarget, 2016, 7, 59441-59457.	0.8	7
59	HLA Class II Histocompatibility Antigen \hat{I}^3 Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer. Cancers, 2021, 13, 6179.	1.7	7
60	Drug transporters in breast cancer: response to anthracyclines and taxanes. Expert Review of Anticancer Therapy, 2015, 15, 1075-1092.	1.1	6
61	Clinical Proteomics. Molecular and Cellular Proteomics, 2008, 7, 1779-1779.	2.5	6
62	Proteomic analysis of urinary fibrinogen degradation products in patients with urothelial carcinomas. Clinical Proteomics, 2006, 2, 45-65.	1.1	4
63	Proximity probing assays for simultaneous visualization of protein complexes <i>in situ </i> Review of Proteomics, 2013, 10, 219-221.	1.3	4
64	Comparative Analysis of Evolutionarily Conserved Motifs of Epidermal Growth Factor Receptor 2 (HER2) Predicts Novel Potential Therapeutic Epitopes. PLoS ONE, 2014, 9, e106448.	1.1	3
65	Challenges and Opportunities in Oncoproteomics. Molecular Oncology, 2010, 4, 459-460.	2.1	2
66	Looking back, to go forward. Molecular Oncology, 2014, 8, 445-446.	2.1	2
67	Cell of the month: Transformed human epithelial cells. Nature Cell Biology, 2004, 6, 1163-1163.	4.6	O
68	Image competition. Nature Reviews Molecular Cell Biology, 2004, 5, 957-957.	16.1	0
69	8Characterization of Activated Stroma Cells and Externalized Proteins in 3D Human Breast Cancer Model. Apmis, 2008, 116, 421-421.	0.9	0
70	Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-1 level: Results from the NORDIC VII study Journal of Clinical Oncology, 2014, 32, 3590-3590.	0.8	0